Displaying drugs 626 - 650 of 749 in total
AT9283
AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.
Investigational
TAK-751S
TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic Escherichia coli.
Investigational
Ilodecakin
Investigational
Astaxanthin
Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. It is found in the majority of aquatic organisms with red pigment. Astaxanthin has shown to mediate anti-oxidant and anti-inflammatory actions. It may...
Investigational
Bivatuzumab
Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6. [A31688,A31689]
Investigational
Tamibarotene
Tamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.
Investigational
Gantacurium
Gantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.
Investigational
PRTX-100
PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases. These binding interactions enable the compound to modulate the function of these cells and restore the balance of the...
Investigational
Transcrocetinate
Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.
Investigational
Tezacitabine
A synthetic purine nucleoside analogue with potential antineoplastic activity.
Investigational
IGN301
IGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers).
Investigational
Atl146e
ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.
Investigational
VB2-011
VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma. This drug includes the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG).
Investigational
CT-011
CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
Investigational
Varlitinib
Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.
Investigational
Filanesib
Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.
Investigational
ZEN-012
ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors.
Investigational
AZD-8330
AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.
Investigational
DTS-201
DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment.
DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially...
Investigational
Apatorsen
Apatorsen is a second generation antisense drug which in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27) a cell survival protein found at elevated levels in many human cancers including prostate, lung, breast, ovarian, bladder, renal, pancreatic, multiple myeloma and liver cancer.
Investigational
IRL-1620
SPI-1620 is an endothelin B receptor agonist. In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. It is being developed as an adjunct to chemotherapy.
Investigational
Glesatinib
Investigational
Otilimab
Investigated for the treatment of osteoarthritis and rheumatoid arthritis (RA).
Investigational
Apoptone
Investigational
Methoxyamine
Investigational
Displaying drugs 626 - 650 of 749 in total